Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

Publication date: 12 February 2018
Source:Cancer Cell, Volume 33, Issue 2
Author(s): Mariana Salatino, María Romina Girotti, Gabriel A. Rabinovich
The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.

Teaser

The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.


from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2H9lxBj